HIV-1-infection Trials in the USA, 2026
Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.
About this register
This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,141 studies in total at the last sync on 17 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.
This page shows the 25 of those studies listing the condition HIV-1-infection.
How many HIV-1-infection trials are recruiting in the US?
7 of the 25 studies on this page are recruiting new participants as of the 17 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 17 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.
Summary by phase
| Phase | Studies | Recruiting | Share |
|---|---|---|---|
| Phase 3 | 8 | 1 | 32% |
| Phase 2/3 | 6 | 1 | 24% |
| Phase 1 | 5 | 3 | 20% |
| Phase 2 | 5 | 2 | 20% |
| Observational | 1 | 0 | 4% |
Most active sponsors
| Lead sponsor | Studies | Recruiting |
|---|---|---|
| Gilead Sciences | 16 | 5 |
| Merck Sharp & Dohme LLC | 4 | 0 |
| BioNTech SE | 2 | 2 |
| Calimmune, Inc. | 1 | 0 |
| Excision BioTherapeutics | 1 | 0 |
| TaiMed Biologics Inc. | 1 | 0 |
Top states
| State | Studies |
|---|---|
| California | 19 |
| Georgia | 19 |
| Florida | 18 |
| District of Columbia | 13 |
| Missouri | 10 |
| Colorado | 8 |
| Michigan | 8 |
| Arizona | 7 |
| Connecticut | 7 |
| Illinois | 7 |